CD274 and renal cell carcinoma: While belzutifan is already FDA-approved for patients with von Hippel-Lindau (VHL) disease who require therapy for associated RCC, based on a phase 2, open-label, single-group trial (67), a phase 3 study comparing the drug with everolimus in advanced RCC after PD-1/PD-L1 therapy and TKI is underway (NCT04195750).